Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121758 | PMC |
| http://dx.doi.org/10.1016/j.jaad.2023.01.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis.
Dermatol Ther (Heidelb)
September 2025
Incyte Biosciences Canada Corporation, Pointe-Claire, QC, Canada.
Introduction: Atopic dermatitis (AD) is a chronic, highly pruritic, relapsing inflammatory disease associated with high quality-of-life burden. Topical 1.5% ruxolitinib cream is a selective Janus kinase (JAK)1/JAK2 inhibitor that is well tolerated and effective in improving itch and lesion clearance in patients ≥ 12 years old.
View Article and Find Full Text PDFEfficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized Study.
Dermatol Ther (Heidelb)
September 2025
Bayer, Pharmaceuticals, Research and Development, Translational Medicine, Berlin, Germany.
Introduction: Interleukin-1 receptor-associated kinase 4 (IRAK4) is expressed in various immune cells and regulates proinflammatory cytokine production. Its inhibition represents a novel, promising therapeutic option in the treatment of atopic dermatitis (AD). Zabedosertib (BAY1834845) is a potent, selective IRAK4 inhibitor that suppresses markers of local and systemic immune responses.
View Article and Find Full Text PDFEfficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.
Am J Clin Dermatol
September 2025
Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Background: Upadacitinib is an oral selective Janus kinase inhibitor approved to treat moderate-to-severe atopic dermatitis (AD) in adults and adolescents; long-term efficacy and safety data beyond 1 year are needed.
Objective: The aim was to evaluate the long-term efficacy and safety of upadacitinib treatment through 140 weeks in patients with moderate-to-severe AD.
Methods: Measure Up 1 (MeUp1; NCT03569293), Measure Up 2 (MeUp2; NCT03607422), and AD Up (NCT03568318) are ongoing, phase 3, randomized clinical trials evaluating upadacitinib 15 mg (UPA15) and 30 mg (UPA30) in adults and adolescents with moderate-to-severe AD.
Phenotyping of asthma population based on inflammatory blood biomarkers and characterisation of phenotypes depending on asthma control, frequency of exacerbations, and associated comorbidities.
Lung India
September 2025
Department of Pulmonary Medicine, P D Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai, Maharashtra, India.
Background And Objective: There are very few studies in the Indian population on the prevalence of phenotypes in asthma patients. To phenotype patients with bronchial asthma and characterise the phenotypes based on asthma control, exacerbation frequency, and associated comorbidities.
Methods: The current cross-observational study was conducted between January 2022 and June 2022 in the department of pulmonary medicine in a tertiary care hospital.
Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (SEASIDE CHINA): initial two-week dosing, followed by two-week or four-week dosing.
Br J Dermatol
September 2025
Connect Biopharma LLC, San Diego, CA, USA.
Background: Rademikibart (CBP-201) is a potent, next-generation, optimized IL-4Rα-targeting antibody.
Objectives: To evaluate rademikibart efficacy and safety, initially dosed every other week (Q2W), and Q2W or every fourth week (Q4W) from Week 16, in Chinese adults/adolescents with moderate-to-severe atopic dermatitis (AD).
Methods: SEASIDE CHINA (NCT05017480) was a phase II trial: Stage 1 (16-week treatment period), Stage 2 (36-week treatment and 8-week follow-up periods).